1. Home
  2. HALO

HALO

Halozyme Therapeutics Inc.

Logo Halozyme Therapeutics Inc.

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Nasdaq

as 04-16-2024 4:00pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.

Founded: 1998 Country:
United States
United States
Employees: N/A City: SAN DIEGO
Market Cap: 4.9B IPO Year: N/A
Target Price: $53.00 AVG Volume (30 days): 1.2M
Analyst Decision: Buy Number of Analysts: 7
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: 2.10 EPS Growth: 45.83
52 Week Low/High: $29.85 - $45.00 Next Earning Date: 05-07-2024
Revenue: $829,253,000 Revenue Growth: 25.62%
Revenue Growth (this year): 17.39% Revenue Growth (next year): 13.62%

Share on Social Networks: